Sustained delivery formulations of risperidone compound
The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be infected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.
1. A method of treating schizophrenia in a subject in need thereof, the method comprising subcutaneously injecting the subject with a composition comprising about 15 wt % of risperidone base in a solution comprising: (i) about 45 wt % of an 80/20 poly(DL-lactide-co-glycolide) having a carboxy terminal group; and (ii) about 55 wt % of N-methyl-2-pyrrolidone.
2. The method of claim 1 , wherein the composition comprises 15 wt % of risperidone base in a solution comprising: (i) 45 wt % of an 80/20 poly(DL-lactide-co-glycolide) having a carboxy terminal group; and (ii) 55 wt % of N-methyl-2-pyrrolidone.
3. The method of claim 1 , wherein the composition comprises about 90 mg or about 120 mg of risperidone base.
4. The method of claim 1 , wherein the composition comprises about 90 mg of risperidone base.
5. The method of claim 1 , wherein the composition comprises about 120 mg of risperidone base.
6. The method of claim 1 , wherein the copolymer has an average molecular weight from about 10,000 Daltons to about 45,000 Daltons.
7. The method of claim 1 , wherein the copolymer has an average molecular weight from about 15,000 Daltons to about 40,000 Daltons.
8. The method of claim 1 , comprising subcutaneously injecting the subject with the composition once per month.
9. The method of claim 1 , wherein the subject is not administered a supplemental daily oral dose of risperidone.
10. The method of claim 1 , wherein the subject is not administered a supplemental daily oral dose of risperidone for the first twenty-one days of the method of treating schizophrenia.
11. The method of claim 1 , wherein the method provides therapeutic plasma risperidone levels immediately after injection.
12. The method of claim 1 , wherein the method provides steady-state risperidone plasma levels from four to six weeks.